A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00092352|
Recruitment Status : Completed
First Posted : September 27, 2004
Last Update Posted : May 9, 2017
|Condition or disease||Intervention/treatment||Phase|
|Osteoarthritis||Drug: MK0966, rofecoxib Drug: Comparator: celecoxib, placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||395 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee|
|Actual Study Start Date :||April 29, 2003|
|Primary Completion Date :||December 1, 2003|
|Study Completion Date :||December 1, 2003|
- Osteoarthritis (OA) of the knee as measured by Patient Global Assessment of Response to Therapy (PGART) and WOMAC VA 3.0 over 6 weeks of treatment.
- OA of the knee as measured by PGART over 6 wks of treatment.
- WOMAC Question #1 over 6 wks of treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00092352
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|